Melbourne Clinical Trials
The Cannabidiol Study
The study drug is a potential new treatment for epilepsy using cannabidiol (CBD).
4 x 3 nights
8 visits
Kidney fibrosis is an outcome of all advanced chronic kidney disease and there has been a rapid increase in the incidence of chronic kidney disease in recent years.
Currently approved drugs for kidney fibrosis can lead to hyperkalaemia (too much potassium in the blood) and acute kidney failure. These drugs can also only partially slow down the progression of
kidney fibrosis. The need for development of safer and more effective treatments is particularly urgent.
Eligibility
Biological Sex Healthy males
Age 18 - 55 years old
BMI 18 - 32 kg/m²
Weight > 50 kg
Medical History No significant medical history
Medications Not taking any prescription medication
Smoking History Non-smokers or haven't smoked in last 1 month